Journal article

Lamotrigine can be beneficial in patients with Dravet syndrome

Linda Dalic, Saul A Mullen, Eliane Roulet Perez, Ingrid Scheffer

Developmental Medicine & Child Neurology | WILEY | Published : 2015

Abstract

Dravet syndrome, a severe infantile epilepsy syndrome, is typically resistant to anti-epileptic drugs (AED). Lamotrigine (LTG), an AED that is effective for both focal and generalized seizures, has been reported to aggravate seizures in Dravet syndrome. Therefore, LTG is usually avoided in Dravet syndrome. We describe two adults and a child with Dravet syndrome in whom LTG resulted in decreased seizure duration and frequency. This benefit was highlighted in each patient when LTG was withdrawn after 6 to 15 years, and resulted in an increased frequency of convulsive seizures together with longer seizure duration. A 25-year-old male required hospital admission for frequent seizures for the fir..

View full abstract

Grants

Funding Acknowledgements

We thank the patients and their families for their assistance in this study. Funding was provided by the National Health and Medical Research Council of Australia. Florey Institute of Neuroscience and Mental Health is supported by Victorian State Government Infrastructure Funds.Dr Ingrid Scheffer may accrue future revenue on a pending patent re: Therapeutic compound; has received speaker honoraria from Athena Diagnostics, UCB, GSK and Transgenomics; has received funding for travel from Athena Diagnostics, UCB, GSK.